WO2015092335A3 - Proteines recombinantes possedant une activite de facteur h - Google Patents

Proteines recombinantes possedant une activite de facteur h Download PDF

Info

Publication number
WO2015092335A3
WO2015092335A3 PCT/FR2014/053484 FR2014053484W WO2015092335A3 WO 2015092335 A3 WO2015092335 A3 WO 2015092335A3 FR 2014053484 W FR2014053484 W FR 2014053484W WO 2015092335 A3 WO2015092335 A3 WO 2015092335A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
activity
recombinant proteins
recombinant
relates
Prior art date
Application number
PCT/FR2014/053484
Other languages
English (en)
Other versions
WO2015092335A2 (fr
Inventor
Toufik ABACHE
Original Assignee
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Francais Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Francais Du Fractionnement Et Des Biotechnologies
Priority to EP14830995.8A priority Critical patent/EP3083664A2/fr
Priority to JP2016541495A priority patent/JP2017500049A/ja
Priority to US15/105,829 priority patent/US20170190753A1/en
Priority to CA2934558A priority patent/CA2934558A1/fr
Publication of WO2015092335A2 publication Critical patent/WO2015092335A2/fr
Publication of WO2015092335A3 publication Critical patent/WO2015092335A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une protéine recombinante possédant une activité de facteur H.
PCT/FR2014/053484 2013-12-20 2014-12-19 Proteines recombinantes possedant une activite de facteur h WO2015092335A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP14830995.8A EP3083664A2 (fr) 2013-12-20 2014-12-19 Proteines recombinantes possedant une activite de facteur h
JP2016541495A JP2017500049A (ja) 2013-12-20 2014-12-19 Ｈ因子活性を有する組換えタンパク質
US15/105,829 US20170190753A1 (en) 2013-12-20 2014-12-19 Recombinant proteins having factor h activity
CA2934558A CA2934558A1 (fr) 2013-12-20 2014-12-19 Proteines recombinantes possedant une activite de facteur h

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1363351 2013-12-20
FR1363351A FR3015484A1 (fr) 2013-12-20 2013-12-20 Proteines recombinantes possedant une activite de facteur h

Publications (2)

Publication Number Publication Date
WO2015092335A2 WO2015092335A2 (fr) 2015-06-25
WO2015092335A3 true WO2015092335A3 (fr) 2015-12-03

Family

ID=50489269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2014/053484 WO2015092335A2 (fr) 2013-12-20 2014-12-19 Proteines recombinantes possedant une activite de facteur h

Country Status (6)

Country Link
US (1) US20170190753A1 (fr)
EP (1) EP3083664A2 (fr)
JP (2) JP2017500049A (fr)
CA (1) CA2934558A1 (fr)
FR (1) FR3015484A1 (fr)
WO (1) WO2015092335A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
AR094778A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteínas con glicosilación modificada y métodos para producirlas
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ アフィニティークロマトグラフィーマトリックス
US10988519B2 (en) * 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
HUE056019T2 (hu) * 2015-12-23 2022-01-28 eleva GmbH Polipeptidek komplement aktiváció gátlására
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3586860A1 (fr) * 2018-06-22 2020-01-01 Universität Ulm Inhibiteurs de complément et leurs utilisations
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
MX2022004939A (es) * 2019-10-23 2022-08-10 Gemini Therapeutics Sub Inc Metodos para tratar pacientes que tienen mutaciones de cfh con proteinas de cfh recombinantes.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142362A1 (fr) * 2012-03-19 2013-09-26 The Trustees Of The University Of Pennsylvania Régulateur d'activation du complément et ses utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523640T3 (es) * 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
GB0922659D0 (en) * 2009-12-24 2010-02-10 Univ Edinburgh Factor H

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142362A1 (fr) * 2012-03-19 2013-09-26 The Trustees Of The University Of Pennsylvania Régulateur d'activation du complément et ses utilisations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. Q. SCHMIDT ET AL: "Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties", THE JOURNAL OF IMMUNOLOGY, vol. 190, no. 11, 1 June 2013 (2013-06-01), pages 5712 - 5721, XP055072048, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1203548 *
C. Q. SCHMIDT ET AL: "Translational Mini-Review Series on Complement Factor H: Structural and functional correlations for factor H", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 151, no. 1, 7 December 2007 (2007-12-07), pages 14 - 24, XP055218093, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2007.03553.x *
M. HEBECKER ET AL: "An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 2, 15 July 2013 (2013-07-15), pages 912 - 921, XP055072052, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1300269 *
M. K. PANGBURN ET AL: "Molecular Mechanisms of Target Recognition in an Innate Immune System: Interactions Among Factor H, C3b, and Target in the Alternative Pathway of Human Complement", THE JOURNAL OF IMMUNOLOGY, vol. 164, no. 9, 1 May 2000 (2000-05-01), pages 4742 - 4751, XP055218095, ISSN: 0022-1767, DOI: 10.4049/jimmunol.164.9.4742 *
OKEMEFUNA ET AL: "The Regulatory SCR-1/5 and Cell Surface-binding SCR-16/20 Fragments of Factor H Reveal Partially Folded-back Solution Structures and Different Self-associative Properties", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 375, no. 1, 27 November 2007 (2007-11-27), pages 80 - 101, XP022365010, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2007.09.026 *
SHARMA A K ET AL: "IDENTIFICATION OF THREE PHYSICALLY AND FUNCTIONALLY DISTINCT BINDING SITES FOR C3B IN HUMAN COMPLEMENT FACTOR H BY DELETION MUTAGENESIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 93, no. 20, 1 October 1996 (1996-10-01), pages 10996 - 11001, XP002035068, ISSN: 0027-8424, DOI: 10.1073/PNAS.93.20.10996 *

Also Published As

Publication number Publication date
CA2934558A1 (fr) 2015-06-25
JP2020014468A (ja) 2020-01-30
FR3015484A1 (fr) 2015-06-26
EP3083664A2 (fr) 2016-10-26
JP2017500049A (ja) 2017-01-05
US20170190753A1 (en) 2017-07-06
WO2015092335A2 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2015092335A3 (fr) Proteines recombinantes possedant une activite de facteur h
HK1224178A1 (zh) 環肽作為蛋白質靶向劑
EP2981543A4 (fr) Nouveaux antagonistes peptidiques d' 4 7
MX2019003214A (es) Formulaciones de proteina de inmunoglobulina del dominio variable dual estable.
WO2014191113A8 (fr) Nouveaux anticorps
EP3578570A4 (fr) Protéine multifonctionnelle
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
EP3033098A4 (fr) Protéines de facteur viii de recombinaison
EP3589640A4 (fr) Purification de protéines avec la protéine l
EP3375873A4 (fr) Polypeptide se liant aux immunoblobulines
EP3562299A4 (fr) Protéines insecticides
EP2964775A4 (fr) Promoteurs de levure pour l'expression d'une protéine
HK1231494A1 (zh) 殺蟲融合蛋白改進
EP3302468A4 (fr) Analogues à petites molécules du peptide de liaison nemo
EP3708667A4 (fr) Protéine de liaison à l'immunoglobuline
EP3463414A4 (fr) Interfaces de protéines
HK1220492A1 (zh) 重組多肽生產
EP3377633C0 (fr) Production de protéines recombinantes
EP2976622A4 (fr) Étalon protéique
EP3120147A4 (fr) Dosage de protéines glyquées
EP3061771A4 (fr) Nouveau peptide à quatre épitopes ctl
EP3049512A4 (fr) Plate-forme de purification et d'expression de protéines sur la base du séparatome de e. coli
EP3330376A4 (fr) ANTICORPS ANTI-PROTÉINE Eva1
ZA202003722B (en) Modified globin proteins
EP3364744A4 (fr) Espèce d'avoine à teneur élevée en protéines

Legal Events

Date Code Title Description
REEP Request for entry into the european phase

Ref document number: 2014830995

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014830995

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14830995

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2934558

Country of ref document: CA

Ref document number: 2016541495

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15105829

Country of ref document: US